NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-08-31
Reading TMO? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Intact: The reason to own it still holds.
Thermo Fisher grows sales about 7% a year, helped by acquisitions like Clario. Profit margins stay solid with EPS near $25 in 2026. Cash from operations rose from $723 million to $1.192 billion in one year. The company keeps buying back shares to return capital.
Growth could slow if acquisitions like Clario do not integrate well. Profit margins might weaken if costs rise or demand softens. Cash flow growth could stall, limiting share buybacks and investments.
The price is about 8% above our fair value near $479 and below the Street median of $555. Analysts expect about 7.5% revenue growth, which aligns with recent trends. Our view is more cautious than the Street on valuation but agrees on steady growth.
Breaks if: No buyback program announced or executed in next year
Breaks if: Quarterly cash from operations falls below $1 billion
EPS falls below $23 next year
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on growth through acquisitions and innovation. The current thesis state is stable, supported by strong recent financial results and ongoing management priorities.
The market appears to have a neutral valuation stance on TMO, reflecting a slight premium compared to peers. There is a minor expectations gap, suggesting that the market is not overly optimistic or pessimistic about future performance.
Fundamentals are likely to remain strong, driven by management's focus on strategic acquisitions and disciplined capital allocation. However, there is a moderate risk due to potential guidance cuts and ongoing economic conditions.
The thesis hinges on the performance of the broader healthcare sector and whether key competitors continue to deliver strong earnings. Additionally, TMO's ability to maintain its growth trajectory through innovation and acquisitions will be crucial.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. The company is advancing its growth strategy with innovative product launches. Stronger demand for biosimilars in India is also a key driver. This growth is expected to continue over the next five years.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: YoY revenue growth falls below 5% next year
The outlook for TMO over the next 1 to 3 years is shaped by its strong recent performance and strategic initiatives. Not investment advice.
